RLM.L Regulatory News (RLM)

23 Apr 2008 07:01

PuriCore Plc23 April 2008 PuriCore to Present Clinical Case Findings for Vashe(R) Wound Therapy at SAWC Three Conference Posters Plus Lecture Sessions on Hypochlorous Acid Solutions in Wound Management MALVERN, PENNSYLVANIA, AND STAFFORD, UK, April 23, 2008 - PuriCore (LSE: PURI),the life sciences company focused on the control of infectious pathogens withits patented, safe, and natural antimicrobial technology, will feature itslatest developments and clinical results for its proprietary Vashe Wound TherapySolution at the Symposium on Advanced Wound Care this week in San Diego,California. PuriCore's technology mimics the human body's production of thenatural antimicrobial hypochlorous acid. Hypochlorous acid is highly effectiveagainst a broad range of microorganisms including MRSA, VRE, and numerous otherbacteria, viruses, and fungal spores. The Vashe Wound Therapy Solution is designed as a safe and effectivenon-cytotoxic, non-sensitizing, wound treatment specifically aimed at managingthe wound environment. To date, it has been used in more than 2,500 clinicalcases including chronic and acute wounds. The data reflect the positive impactthe Vashe Wound Therapy Solution has on the wound environment and subsequently,the healing process. Michel H.E. Hermans, MD, a worldwide thought leader inwounds and burn care, will present these clinical results at the PuriCore Booth#1103 throughout the conference. Additionally, Jeffrey Niezgoda, MD, FACHM, FAPWCA, FACEP, a leading woundmanagement physician, will present three poster/abstracts at this conferencerelated to his clinical experience using the Vashe Wound Therapy Solution aspart of the plan of care in managing a broad range of acute and chronic wounds: • "Hypochlorous Acid Solution Improves Wound Healing Trajectories" • "Hypochlorous Acid Solution is Effective in the Treatment of Chronic Venous Ulcers" • "Hypochlorous Acid Enhances the Treatment of Necrotizing Soft Tissue Wounds" "Our research indicates that hypochlorous acid represents a new and effectiveclass of treatment for hard-to-heal wounds," said Greg Bosch, CEO of PuriCore. "We are very pleased with our promising clinical results showing both safety andpotential therapeutic value in the management of such a wide variety of chronicand acute wounds, and we look forward to expanding our clinical work in thisarea." About the Vashe Wound Therapy System PuriCore's patented wound therapy technology is being commercialized as theVashe Wound Therapy System, a novel, noninvasive, easy-to-use wound managementprocess that has been shown to be complementary to existing treatment methods.The Vashe System is an FDA-cleared medical device used for moistening,irrigating, cleaning, and debriding acute and chronic wounds including stage Ithrough IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgicalwounds, first and second degree burns, abrasions, and minor irritations of theskin. The Vashe Solution mimics the human body's own infection fighter,hypochlorous acid. Research to date demonstrates that the Vashe Solutionprovides a safe and effective alternative to cytotoxic antimicrobial andantiseptic products currently used to treat infected wounds and surgical sitesand is an important element in the overall clinical process of effective woundmanagement. About PuriCore PuriCore (LSE: PURI) is a life sciences company focused on developing andcommercializing proprietary products that safely, effectively, and naturallykill contagious pathogens. PuriCore's technology provides a solution to a broadrange of markets that depend upon controlling contamination, including foodsafety in retail and foodservice, medical device disinfection, wound therapy,and hospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,Norovirus, Avian Influenza, HIV, Polio Virus, Helicobacter pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit PuriCore's websiteat www.puricore.com, which does not form part of this press release. Contacts:Financial DynamicsBen Brewerton+44 (0)20 7831 3113 This information is provided by RNS The company news service from the London Stock Exchange